Sorenson, Corinna (2009) The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro observer, 11 (1). pp. 1-4. ISSN 1020-7481
Since the late 1970s, many European countries have established health technology assessment (HTA) systems to inform coverage and pricing decisions. These countries use HTA to systematically determine the relative ‘value for money’ provided by new technologies and to give providers and patients information to make treatment choices. This, in turn, serves to encourage the efficient and effective use of health technologies and to support innovation by identifying and rewarding high-value products. This overview article explores the use of HTA in coverage and pricing decisions, with a focus on pharmaceuticals, in six European countries with established HTA systems – Denmark, England, France, Germany, the Netherlands and Sweden.
|Additional Information:||© 2009 European Observatory on Health Systems and Policies|
|Library of Congress subject classification:||T Technology > T Technology (General)
R Medicine > RA Public aspects of medicine
|Sets:||Research centres and groups > LSE Health|
Actions (login required)
|Record administration - authorised staff only|